The decreased serum activity of cytosolic 5′-nucleotidase IA as a potential marker of breast cancer-associated muscle inflammation

• Published in: Nucleosides, nucleotides & nucleic acids Vol. 41; no. 3; pp. 273 - 284
• Main Authors: Jędrzejewska, Agata, Kutryb-Zając, Barbara, Król, Oliwia, Harasim, Gabriela, Frańczak, Marika, Jabłońska, Patrycja, Słomińska, Ewa, Smoleński, Ryszard Tomasz
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2022; Taylor & Francis Ltd
• Subjects: 5'-Nucleotidase - metabolism; Adenosine; AMP; anti-NT5C1A autoantibody; Autoantibodies; Biomarkers; Breast cancer; Breast Neoplasms; cN-IA; Cytosolic 5′-nucleotidase 1A; Female; Humans; Inflammation; Muscles - metabolism; Myocytes; Nucleotidase; Paraneoplastic syndrome; Polymyositis; Skeletal muscle; breast cancer; polymyositis; anti-NT5C1A autoantibody; cN-IA; Cytosolic 5′-nucleotidase 1A
• ISSN: 1525-7770; 1532-2335
• DOI: 10.1080/15257770.2021.2007396

Cytosolic 5′-nucleotidase IA (cN-IA) plays a central role in the regulation of the purine nucleotide pool in skeletal muscle, preferentially converting adenosine monophosphate to adenosine. cN-IA can act as an autoantigen in muscle diseases, including the paraneoplastic syndrome related to breast cancer (BC). As a result of myocyte damage, released cN-IA protein may trigger the production of anti-cN-IA antibodies (anti-NT5C1A). This work aimed to develop an effective method to measure cN-IA activity in the serum and analyze it in BC patients. Our study demonstrated that serum cN-IA activity was decreased in BC patients and we assumed it is due to the presence of specific autoantibodies. We found correlations between cN-IA activity and parameters of inflammatory muscle damage. Thus, cN-IA is worth further attention to clarify its usefulness as a biomarker of BC-associated polymyositis.